How candidacy for ChondroFiller injection is assessed

Suitability for ChondroFiller™ (Liquid Cartilage™) injection is assessed against a specific set of biological, systemic, and mechanical conditions — and understanding what those conditions are makes the exclusion logic that follows far more intuitive. ChondroFiller is a Class III medical device: an acellular murine collagen scaffold that, once placed under ultrasound guidance in an outpatient setting, gels in situ and recruits the patient's own progenitor cells from the synovium and subchondral bone — a process known as acellular matrix-induced chondrogenesis. Anything that disrupts that recruitment, degrades the scaffold before integration occurs, or places unpredictable mechanical forces on the repair site represents a reason to pause or redirect. A structured clinical assessment — typically combining weight-bearing X-ray, MRI, and a biomechanical review — identifies which category of concern applies and what the appropriate next step is. Being found unsuitable for ChondroFiller injection is a clinical finding, not a closed door: alternative injection pathways are available and are matched to the clinical picture. Where specific thresholds appear in subsequent sections (such as alignment tolerances), these reflect clinical guidance and device-class inference rather than RCT-level contraindication data specific to ChondroFiller — the mechanistic reasoning is consistent across sources, but that context is worth carrying through the whole article.

Absolute contraindications — the hard stops

The hard stops for ChondroFiller injection fall into three groups: biological incompatibility with the scaffold material, active infection, and pregnancy or breastfeeding.

Collagen hypersensitivity. The scaffold is manufactured from murine-derived Type I collagen. Confirmed or suspected allergy to animal-derived collagen makes injection unsafe — not merely inadvisable. A history of worsening symptoms, rash, or systemic signs after any previous collagen-based procedure must be declared before a treatment plan is agreed; the post-injection distinction between normal 24-hour swelling and a true allergic response matters, but prior hypersensitivity removes the option entirely.

Active infection. Any active intra-articular infection (septic arthritis) or uncontrolled systemic infection rules out intra-articular injection of any kind. Placing a biological scaffold into an infected environment risks bacterial colonisation of the matrix and its degradation before cellular integration can begin — the mechanism is direct, not incidental.

Pregnancy and breastfeeding. Safety data for injectable collagen scaffolds in either group are absent. The exclusion reflects an unquantifiable unknown rather than a demonstrated harm, but in pregnancy an unquantifiable unknown is treated as an unacceptable risk.

Inflammatory arthropathy and crystal-deposition disease. Active rheumatoid arthritis, psoriatic arthritis, gout, and calcium pyrophosphate deposition disease (CPPD) present the same fundamental problem: the joint chemistry during active disease — sustained inflammatory mediator load or crystal-driven enzymatic activity — degrades the collagen matrix before the body's progenitor cells can populate and stabilise it. This is a hostile local environment for the scaffold itself, not simply a systemic concern about the patient. Managing the underlying condition to a quiescent state may re-open candidacy; an active flare does not.

None of these factors can be managed around at the injection stage.

Systemic health conditions that affect candidacy

These conditions differ in character from those covered above. Rather than making the scaffold itself unsafe, they reduce or eliminate the healing response the device depends on — and without adequate progenitor cell recruitment, the scaffold cannot be populated and integrated as intended.

Active malignancy is an exclusion across regenerative injection therapies. Oncological proliferative signalling conflicts with the controlled, directed cell differentiation that matrix-induced chondrogenesis requires; no scaffold-based repair pathway is appropriate while malignant disease is active.

Severe immunosuppression — whether disease-driven or medication-driven — impairs the same progenitor cell response. The mechanism applies regardless of the underlying cause: reduced recruitment means the collagen scaffold remains unpopulated rather than remodelled into load-bearing tissue.

Poorly controlled diabetes carries a similar effect on healing biology, limiting progenitor cell availability and tissue repair capacity. The clinical nuance matters for patients reading this: poorly controlled blood glucose is the concern, not diabetes per se. Patients with well-managed diabetes are not automatically excluded but require individual assessment before treatment is agreed.

Unmanaged coagulation disorders, or the need for continuous therapeutic anticoagulation, call for individual screening before any intra-articular injection. This is a procedural consideration specific to the injection setting rather than an incompatibility with the collagen material itself.

Patient expectations are also assessed at candidacy stage. Platform sources flag this explicitly: the scaffold supports the body's own repair processes over months, not days, and patients expecting immediate or guaranteed pain relief are poorly matched to a treatment whose clinical benefit accumulates over time. Realistic understanding of the timeline is part of safe patient selection.

Mechanical joint factors that must be resolved first

Mechanical factors occupy a distinct category in the candidacy screen. Unlike the hard stops covered in the preceding sections, they rarely close the door permanently — what they require is a detour, a prerequisite resolved first and candidacy reassessed once it has been.

Ligament instability. Unresolved laxity in the ACL, PCL, or MCL is the single factor most consistently identified across clinical sources as undermining ChondroFiller outcomes. An unstable joint transmits unpredictable force patterns through the repair site with every step, and progenitor cells migrating into the scaffold require a mechanically stable micro-environment to differentiate appropriately. Stabilising the joint — through reconstruction or supported rehabilitation where this is appropriate — is the described pathway; it is a redirection, not a permanent rejection.

Coronal malalignment. Significant varus or valgus deviation concentrates load into one compartment and overwhelms the scaffold before integration can occur. Clinical guidance cites approximately 5° as a threshold for concern, though this figure reflects clinical consensus rather than a manufacturer-stated IFU specification. Where malalignment is the dominant driver of wear, high tibial osteotomy (HTO for varus deformity) or distal femoral osteotomy (DFO for valgus) is the typical prerequisite — a knee-preserving step that redistributes load before ChondroFiller delivery is reconsidered.

Meniscal deficiency. The meniscus distributes load across the tibial plateau; major loss that is actively driving compartmental overload creates the same hostile mechanical environment as uncorrected malalignment. The clinical question is whether that problem can be addressed — with the scaffold pathway held open until it is.

Establishing which of these factors is present, and to what degree, forms part of the biomechanical workup. Weight-bearing X-ray informs alignment assessment; objective gait analysis can identify dynamic load-distribution patterns that static imaging does not capture.

Factors that do not rule out ChondroFiller injection

Several features that patients commonly expect to rule them out simply do not — and understanding why they don't matters as much as understanding the exclusions covered in earlier sections.

Defect size. The injectable pathway carries no upper limit on cartilage surface area. Arthroscopic cartilage repair targets a contained focal defect within a surgically prepared, dry-field environment; ultrasound-guided ChondroFiller injection works differently, delivering the collagen scaffold top-down across the articular surface in a fluid joint environment. Large areas of diffuse wear are not a barrier — they are closer to the intended indication.

Age. No upper age limit applies to the injectable scaffold pathway. Being in one's 60s, 70s, or beyond does not exclude a patient from assessment.

Advanced radiological OA (KL Grade III–IV). This is the target clinical presentation for the injection form, not a disqualifier. The scaffold is specifically designed for diffuse, advanced joint wear — the population most likely to have been told that joint replacement is the next logical step.

TKR recommendation. Being advised to consider total knee replacement is not itself a contraindication. For patients seeking to postpone or defer that conversation, ChondroFiller injection remains a pathway worth exploring through formal assessment.

Obesity is not listed as a contraindication for ChondroFiller injection, though EUROVISCO consensus identifies it as one of the two chief predictors of poor response to hyaluronic acid viscosupplementation — a distinction worth noting when comparing options.

Alternative injection pathways when ChondroFiller does not fit

For patients ruled out by one or more of the criteria above, the choice of alternative injection follows the reason for exclusion.

Corticosteroid injection is the clearest short-term option for an acutely inflamed knee — effective for rapid pain relief and useful as a pre-procedure measure. The relevant trade-off is well documented: McAlindon and colleagues' 2017 JAMA randomised trial found accelerated cartilage volume loss with repeated triamcinolone, and a 2026 multidisciplinary expert consensus on glucocorticoid use in knee OA reinforces that corticosteroid remains a short-term tool with careful attention to dosing frequency — not a sustained solution.

Hyaluronic acid (HA) viscosupplementation improves joint lubrication symptomatically but clears from the joint within weeks and carries no regenerative mechanism. Guideline opinion is divided: OARSI offers conditional support; AAOS and ACR are more sceptical. EUROVISCO consensus identifies obesity and advanced radiological OA — the profile of many ChondroFiller candidates — as the two chief predictors of a poor HA response, which limits its usefulness as a direct substitute for that population. It serves better as a bridging option while a patient awaits mechanical correction.

PRP injection delivers growth factors to support chondrocyte activity and reduce inflammation. A 2025 systematic review and meta-analysis found generally favourable patient-reported outcomes versus HA at 6 and 12 months. Preparation method matters — leukocyte-poor (LP-PRP) and leukocyte-rich (LR-PRP) formulations behave differently — and the 2025 GRIIP international consensus establishes PRP's own contraindication profile, covering active infection, active malignancy, and certain haematological conditions.

Arthrosamid® (polyacrylamide hydrogel) is the principal structural alternative for patients with established OA who are not suited to scaffold-based repair. It integrates into the synovial lining as a permanent, non-regenerative hydrogel — a different mechanism and a different treatment goal from ChondroFiller. For patients whose priority is long-term symptom reduction rather than an active repair process, that distinction matters. Where separate clinical justification exists for each, the two can in principle be considered alongside one another, though direct combination evidence remains limited.

Which pathway fits depends on why ChondroFiller was excluded: patients with inflammatory arthropathy may need disease management reviewed before any injection is appropriate; those awaiting mechanical correction may consider HA or PRP as a bridge; and those for whom a structural but non-regenerative option suits best are assessed against the Arthrosamid® profile. These distinctions are best worked through at a formal clinical assessment, where imaging, functional history, and comorbidity profile can be weighed together.